Back to top Open menu arrow
Download PDF Reprints

The Journal of
Clinical Psychiatry
Members only

Original Research Focus on Psychosis February 9, 2026

Latency to Long-Acting Injectable Antipsychotic Initiation and Psychiatric Hospitalization in First-Episode Schizophrenia

;

J Clin Psychiatry. 2026;87(1):25m16048

Abstract

Objective: Long-acting injectable (LAI) antipsychotics are increasingly recommended for patients in the early phase of schizophrenia. We examined how the timing of LAI initiation affects treatment discontinuation and hospitalization duration in first-episode schizophrenia.

Methods: Using the Korean Health Insurance Review and Assessment Service claims database, we identified 6,380 patients with first-episode schizophrenia receiving continuous LAI treatment. The interval from diagnosis to LAI initiation was categorized into 6 groups (<1, 1–2, 2–3, 3–4, 4–5, and >5 years). Treatment discontinuation and the proportion of psychiatric hospitalization days during continuous LAI use were analyzed using Cox and linear regression models.

Results: Earlier LAI use increased over time, but the duration of continuous treatment declined. Patients who started LAIs >2 years after diagnosis had lower risks of discontinuation than those within the first year (2–3 years: hazard ratio [HR]=0.77 [0.69–0.87]; 3–4 years: HR=0.77 [0.68–0.86]; 4–5 years: HR=0.70 [0.61–0.79]; >5 years: HR=0.66 [0.59–0.74]). Later initiation was associated with greater psychiatric hospitalization burden, particularly among patients with prior hospitalizations (1–2 years: β=0.039, P=.039; 3–4 years: β=0.057, P=.010; >5 years: β=0.162, P <.001), and within the >5-year group, longer delays further increased hospitalization days (β=1.87×10−4, P<.001).

Conclusion: Although delayed initiation was linked to better treatment adherence, early LAI use reduced hospitalization burden, supporting guidelines advocating earlier LAI treatment in schizophrenia.

J Clin Psychiatry 2026;87(1):25m16048

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Acosta FJ, Hernández JL, Pereira J, et al. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74–82. PubMed CrossRef
  2. Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. PubMed CrossRef
  3. Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. PubMed CrossRef
  4. Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018;44(3):603–619. PubMed CrossRef
  5. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609. PubMed CrossRef
  6. Correll CU, Martin A, Patel C, et al. Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics. Schizophr (Heidelb). 2022;8(1):5. PubMed CrossRef
  7. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3):148–156. PubMed CrossRef
  8. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018;75(6):555–565. PubMed CrossRef
  9. Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829. PubMed CrossRef
  10. Munday J, Greene M, Chang E, et al. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data. Curr Med Res Opin. 2019;35(7):1231–1239. PubMed CrossRef
  11. Kane JM, Chen A, Lim S, et al. Early versus late administration of long-acting injectable antipsychotic agents among patients with newly diagnosed schizophrenia: an analysis of a commercial claims database. Int Clin Psychopharmacol. 2023;38(4):240–248. PubMed CrossRef
  12. Fang SC, Huang CY, Shao YJ. Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia. J Clin Psychiatry. 2022;83(4):21r14153. PubMed CrossRef
  13. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998;172(33):53–59. PubMed CrossRef
  14. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry. 2017;16(3):251–265. PubMed CrossRef
  15. Kim S, Kim S, Koh M, et al. Effects of long-acting injectable paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration. J Clin Psychiatry. 2021;82(1):20m13446. PubMed CrossRef
  16. Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224. PubMed CrossRef
  17. Agid O, Remington G, Fung C, et al. Real-world utilization patterns of long-acting injectable antipsychotics in Canada: a retrospective study. Can J Psychiatry. 2022;67(3):226–234. PubMed CrossRef
  18. Fang CZ, Lau N, Chan JKN, et al. Temporal trends of antipsychotic utilization patterns in 62,607 patients with schizophrenia-spectrum disorders in Hong Kong: an 11-year population-based study with joinpoint regression analysis. J Psychiatr Res. 2025;183:144–149. PubMed CrossRef
  19. Solmi M, Seitidis G, Mavridis D, et al. Incidence, prevalence, and global burden of Schizophrenia-data, with critical appraisal, from the Global Burden of Disease (GBD) 2019. Mol Psychiatry. 2023;28(12):5319–5327. PubMed CrossRef
  20. Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) database for research. J Lipid Atheroscler. 2022;11(2):103–110. PubMed CrossRef
  21. Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213. PubMed CrossRef
  22. Shimomura Y, Kikuchi Y, Suzuki T, et al. Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms. Schizophrenia Res. 2020;215:8–16. PubMed CrossRef
  23. Ha J, Cho S, Shin Y. Utilization of health insurance data in an environmental epidemiology. Environ Health Toxicol. 2015;30:e2015012. PubMed CrossRef
  24. Joo SW, Kim H, Jo YT, et al. Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first-episode schizophrenia: a nationwide, health insurance data-based study. Psychiatry Clin Neurosci. 2022;76(5):195–200. PubMed CrossRef
  25. Joo SW, Kim H, Jo YT, et al. Delay in psychiatric hospitalization from the diagnosis of first-episode schizophrenia and its association with clinical outcomes and direct medical costs: a nationwide, health insurance data-based study. BMC Psychiatry. 2022;22(1):636. PubMed CrossRef
  26. Joo SW, Kim H, Jo YT, et al. Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study. Psychol Med. 2023;53(1):181–188. PubMed CrossRef
  27. Yun J-Y, Lee JS, Kang SH, et al. Korean treatment guideline on pharmacotherapy of co-existing symptoms and antipsychotics-related side effects in patients with schizophrenia. Korean J Schizophrenia Res. 2019;22(2).
  28. Li P, Geng Z, Benson C, et al. Real-world effectiveness of long-acting injectable and oral antipsychotic agents in US Medicare patients with schizophrenia. Adv Ther. 2025;42(2):1251–1264. PubMed CrossRef
  29. Boyer L, Falissard B, Nuss P, et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023;28(9):3709–3716. PubMed CrossRef
  30. Goff DC, Falkai P, Fleischhacker WW, et al. The long-term effects of antipsychotic medication on clinical course in schizophrenia. Am J Psychiatry. 2017;174(9):840–849. PubMed CrossRef
  31. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?. World Psychiatry. 2018;17(2):149–160. PubMed CrossRef
  32. Correll CU, Benson C, Emond B, et al. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophr (Heidelb). 2023;9(1):9. PubMed CrossRef
  33. Stump TA, Nelson LA, Liu Y, et al. The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection. Ment Health Clin. 2021;11(1):12–18. PubMed CrossRef
  34. Doshi JA, Pettit AR, Stoddard JJ, et al. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge. J Clin Psychopharmacol. 2015;35(4):442–446. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Figure. Journal cover highlights articles on bipolar II depression therapy, schizophrenia treatment, and adult ADHD symptoms.

Vol 86 • 2025 • Number 4

Read the Current Issue

Original Research

Effects of Interpersonal and Social Rhythm Therapy on Suicidal Ideation in Adults with Bipolar II Depression

Academic Highlights

Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report

Academic Highlights

Psychosocial Interventions and Functional Recovery in Schizophrenia

Original Research

Symptom Network Analysis of ADHD and Emotional Symptoms in Adults

Original Research

Emory Treatment Resistance Interview for PTSD—Short Version

Original Research

Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
View current Issue

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe